Insys to Pay $225 Million to Settle Opioid-Sales Probe
Insys Therapeutics Inc., grappling with the prospect of bankruptcy after its founder was convicted on racketeering charges, agreed to pay $225 million to settle U.S. claims that the drug maker illegally sold opioid-based painkillers. Under terms of the deal, Insys …